Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

Exclusion criteria

• . Have history of a medical condition (systemic disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding) giving reasonable suspicion of a condition that contraindicates the use of Ixo-vec, compromises the participant's ability to comply with the planned study assessments, or that might affect the interpretation of the results of the study or render the participant at high risk for treatment complications in the opinion of the Investigator. History of severe coronavirus disease of 2019 (COVID-19) infection may meet this exclusion criterion if, in the opinion of the Investigator, it is likely to lead to any of the complications listed above.
• . Received prior gene therapy (other than Ixo-vec, where applicable)
• . Currently receiving steroids at Screening Visit 1 in the previously treated eye (Ixo-vec-experienced participants) or in either eye (Ixo-vec-naïve participants).
• . Received any non-gene IMP or medical device in the contralateral eye (and/or initial eye for Ixo-vec-naïve participants) within 3 months of Screening Visit 1
• . Have history of allergy, hypersensitivity, or contraindications to the use of any product or its excipients administered as part of this study.
• . Have evidence of poorly controlled diabetes or glycated hemoglobin (HbA1c) ≥ 8.0%
• . Have history or evidence of cardiovascular diseases and ongoing bleeding disorders as defined by the protocol.
• . Use of systemic immunosuppressive therapy within a protocol-defined period.